Preparation and characterization of solid lipid nanoparticles loaded with cytarabine via a micellar composition for leukemia

Abstract

Cytarabine is an anticancer drug used in hematological malignancies and lymphoma but its short biological half life demands continuous intravenous infusion or time spaced injection. This would lead to patient incompliances and discomfort. Therefore it is imperative to look for novel therapeutic systems with lesser side effects urgently to address the underlying causes of poor treatment outcomes associated with conventional therapy. Hence entrapping of cytarabine in a solid lipid nanoparticle (SLN) based formulation could be a better alternative to sustain release and improve therapeutic activity by maintaining the plasma level. We chose tristearin as solid lipid and formulated it in nanoparticulate form by an ultrasonic emulsification method. SLN formulations were optimized and characterized for various physiochemical parameters like size (below 200 nm), charge, morphology and entrapment efficiency. An in vitro drug release study through a dialysis bag revealed a prolonged release of cytarabine. A cell line study on HL60 cell showed a significantly higher efficacy of cytarabine SLN as compared to cytarabine solution. Well characterized carriers were further subjected to hemolytic toxicity. Results showed no hemolytic toxicity and good stability at ambient temperature.

Colorectal cancer-targeted delivery of oxaliplatin via folic acid-grafted solid lipid nanoparticles: preparation, optimization, and in vitro evaluation

“…Hence, it was attempted to develop FA grafted SLNs bearing OP for targeted delivery to CRC. Tristearin is a biocompatible and biodegradable solid lipid, which has good stability at physiological temperature [14,15]. Therefore, it was selected to prepare lipid matrix of SLNs.…”

FericipXT-coated PEGylated rutile TiO2 nanoparticles in drug delivery: in vitro assessment of imatinib release

“…Likewise, Li et al 19 synthesized a drug, 5-FU loaded chitosan-coated ZnSe/ZnS NPs (5-Fu–CS–ZnSe/ZnS NPs) and observed that the XRD plot of 5-FU displayed diffraction peaks indicating its crystalline nature, however, no such peak of the drug was obtained in the XRD of 5-Fu–CS–ZnSe/ZnS NPs depicting that the drug was present in its amorphous form onto the functionalized NPs. Raj et al 20 prepared solid-lipid NPs and loaded them with cytarabine, an anticancer drug meant for treating leukemia. The XRD plot obtained for cytarabine was crystalline in nature, but the XRD pattern of the cytarabine-loaded solid-lipid NPs did not show the characteristic peak of cytarabine.…”

Anti-HMG-CoA Reductase, Anti-diabetic, Anti-urease, Anti-tyrosinase and Anti-leukemia Cancer Potentials of Panicolin as a Natural Compound:<i>In vitro</i> and <i>in silico</i> Study

“…Treatment includes a combination of chemotherapy, targeted therapy, radiation therapy, bone marrow transplantation, and palliative care. Certain types of leukemia are treated with conscious anticipation 40) . Blood or platelet products, as well as a pain clinic, may be needed.…”